Possis catheter approval
This article was originally published in The Gray Sheet
Executive Summary
Possis gains PMA supplement approval for AngioJet Spiroflex catheter for removal of blood clots from coronary arteries, the firm announces Jan. 30. Possis will launch Spiroflex through its 80-rep sales force into the roughly $150 million domestic coronary thrombectomy market. Spiroflex offers increased trackability and improved crossing in difficult anatomy compared with earlier versions, as well as quick 360-degree thrombus removal, Possis says. The Minneapolis-based firm expects approval of its SpiroflexVG for use in saphenous vein bypass grafts in the heart and larger native coronary vessels this year...